On December 28, 2014, Egenix, Inc. filed for bankruptcy with the United States Bankruptcy Court for the District of Delaware. As of today’s date, the only document filed with the Court in this action is the petition itself. According to the petition, Egenix has $500,000 to $1 million in estimated assets, and $1 million to $10 million in estimated debts.
Egenix is a privately held biotechnology company focused on developing innovative cancer therapeutics. The company is based in LaGrangeville, New York. Egenix is being represented in this bankruptcy action by the law firm of Cole, Schotz, Meisel, Forman & Leonard, P.A. Stay tuned for further updates on this bankruptcy filing.